Tumor Immunity and Type I IFN

Tumor Immunity and Type I IFN
Author Affiliation: 
PBL Assay Science

The antiproliferative and anti-angiogenic activities of type I interferons have paved the way for the use of these cytokines, in particular IFN-α, in clinical oncology. In some clinical settings, however, IFN-α has been superseded by newer anticancer drugs because of its severe side effects, which include autoimmunity, inflammation and tissue toxicity. IFN-λ1, a member of the type III interferon family, shows promise as an alternative antiviral and antiproliferative agents, as the rela­tively limited expression of its receptor may preclude the hematological toxicity associated with type I interferon. Meanwhile, the recently described effects of type I interferons on DCs and other cells of the immune response support the rationale for using type I interferon molecules as adjuvants for the generation of more effective cancer vaccines.(Click download for a PDF of the image below)

Find your lot-specific Certificate of Analysis here!

Finding the right biomarker detection service to meet your project needs just got easier...

Sign up for our email list to be kept up-to-date on the latest product releases and company news!

Go to top